Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.65 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.64 |
| ▸ | CA9 | Q16790 | 1/20 | 0.64 |
| ▸ | MITF | O75030 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21783150 | 0.93 | PPARG (0.79) | PPARGMAPK1CA9MAOAMAOB | |
| SCHEMBL20534442 | 0.88 | CA9 (0.74) | PPARGMAPK1CA9MITFMAPT | |
| SCHEMBL20534542 | 0.88 | CA9 (0.74) | PPARGMAPK1CA9MITFMAPT | |
| SCHEMBL21783143 | 0.86 | PPARG (1.00) | PPARGMAPK1CA9ALDH1A1SMN1; SMN2 | |
| SCHEMBL22092306 | 0.86 | PPARG (1.00) | PPARGMAPK1CA9ALDH1A1SMN1; SMN2 | |
| SCHEMBL20534421 | 0.83 | MAPT (0.79) | PPARGMAPK1CA9MITFMAPT | |
| SCHEMBL20534423 | 0.83 | MAPT (0.79) | PPARGMAPK1CA9MITFMAPT | |
| SCHEMBL2173013 | 0.81 | BAG3 (0.63) | PPARGMAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2173010 | 0.81 | BAG3 (0.63) | PPARGMAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2172198 | 0.79 | SLC2A1 (0.64) | PPARGMAPTALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200068890-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | LA TROBE UNIVERSITY (AU) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200068890-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | DDC, ODC1, DDT | PPARG 3668/4885MAPK1 463/4885MCHR1 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.